Monopar Therapeutics
MNPR
11 hedge funds and large institutions have $323K invested in Monopar Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
0.04% more ownership
Funds ownership: 0.31% → 0.35% (+0.04%)
31% less capital invested
Capital invested by funds: $471K → $323K (-$148K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
+$69.5K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$14.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$9.58K |
| 4 |
JP Morgan Chase
New York
|
+$7.15K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$2.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.26K |
| 2 |
PWS
Paragon Wealth Strategies
Jacksonville,
Florida
|
-$137 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$24 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $139K | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $59.5K | – | – | – |
|
|
3
Northern Trust
Chicago,
Illinois
| $51.5K | +$2.87K | +194 | +3% |
|
|
KPWS
4
Kestra Private Wealth Services
Austin,
Texas
| $32.6K | +$69.5K | +4,691 | New |
|
|
RRCM
5
Rappaport Reiches Capital Management
Skokie`,
Illinois
| $14.9K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $8.88K | +$9.58K | +647 | +103% |
|
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $7K | +$14.8K | +1,000 | New |
|
8
Morgan Stanley
New York
| $5.56K | – | – | – |
|
|
9
JP Morgan Chase
New York
| $3K | +$7.15K | +483 | New |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $1K | -$6.26K | -423 | -75% |
|
11
Wells Fargo
San Francisco,
California
| $43 | – | – | – |
|
|
PWS
12
Paragon Wealth Strategies
Jacksonville,
Florida
| – | -$137 | -12 | Closed |
|
|
13
Bank of America
Charlotte,
North Carolina
| – | -$24 | -2 | Closed |
|
MNPR Hedge Fund Activity: Q1 2023 in Review
11 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q1 2023, worth a combined $323K — down 31% from $471K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MNPR positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Kestra Private Wealth Services, opening a new position worth an estimated $69.5K. The largest seller was Tower Research Capital (TRC), cutting an estimated $6.26K.
- 11 institutional investors held Monopar Therapeutics (MNPR) as of Q1 2023, up from 10 in Q4 2022.
- Funds reported $323K of Monopar Therapeutics stock for Q1 2023, down 31% quarter-over-quarter.
- 3 funds opened new Monopar Therapeutics positions in Q1 2023 and 2 closed out, a net change of +1 holder.
- The largest Monopar Therapeutics buyer in Q1 2023 was Kestra Private Wealth Services, an estimated $69.5K added.
- The largest Monopar Therapeutics seller in Q1 2023 was Tower Research Capital (TRC), an estimated $6.26K sold.
Based on aggregated 13F filings for Q1 2023.